LGR5 targeting molecules as therapeutic agents for multiple cancer types
H.-C. Chen, N. Mueller, K. Stott, E. Rivers, C. Kapeni, C. M. Sauer, F. Beke, S. Walsh, N. Ashman, L. M. O'Brien, A. R. Fard, A. Godsinia, F. Joud, O. Giger, I. Zlobec, , M. de la Roche
This study develops LGR5-targeting antibodies and therapeutics that effectively kill CRC, HCC, and pre-B ALL cancer cells while sparing normal tissues.
bioRxiv · Sep 1, 2022 · PreprintCell Biology